Rienhoff Hugh JR 4

Accession 0001567619-22-021786

CIK 0001623715other

View on SEC.gov Company Profile

Filed

Dec 18, 7:00 PM ET

Accepted

Dec 19, 4:11 PM ET

Size

29.7 KB

Accession

0001567619-22-021786

Insider Transaction Report

Form 4

Period: 2022-12-15

Imago BioSciences, Inc.IMGO

Rienhoff Hugh JR

DirectorChief Executive Officer

Transactions

Sale
Common Stock
2022-12-15$35.80/sh−206,309$7,385,945→ 489,526 total
Exercise/Conversion
Common Stock
2022-12-16$2.52/sh+144,900$365,148→ 756,310 total
Exercise/Conversion
Stock Option (Right to Buy)
2022-12-15−57,495→ 99,647 total
Exercise: $2.10Exp: 2030-09-09→ Common Stock (57,495 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2022-12-15−46,505→ 96,352 total
Exercise: $1.52Exp: 2029-04-09→ Common Stock (46,505 underlying)
Exercise/Conversion
Common Stock
2022-12-16$2.10/sh+37,440$78,624→ 611,410 total
Sale
Common Stock
2022-12-16$35.78/sh−266,784$9,545,078→ 489,526 total
Exercise/Conversion
Stock Option (Right to Buy)
2022-12-16−84,444→ 11,908 total
Exercise: $1.52Exp: 2029-04-09→ Common Stock (84,444 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2022-12-16−37,440→ 62,207 total
Exercise: $2.10Exp: 2030-09-09→ Common Stock (37,440 underlying)
Exercise/Conversion
Common Stock
2022-12-15$2.52/sh+102,309$257,819→ 649,330 total
Exercise/Conversion
Common Stock
2022-12-15$2.10/sh+57,495$120,740→ 547,021 total
Exercise/Conversion
Common Stock
2022-12-15$1.52/sh+46,505$70,688→ 695,835 total
Exercise/Conversion
Common Stock
2022-12-16$1.52/sh+84,444$128,355→ 573,970 total
Exercise/Conversion
Stock Option (Right to Buy)
2022-12-16−144,900→ 7,415 total
Exercise: $2.52From: 2021-01-01Exp: 2027-03-28→ Common Stock (144,900 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2022-12-15−102,309→ 152,315 total
Exercise: $2.52From: 2021-01-01Exp: 2027-03-28→ Common Stock (102,309 underlying)

Footnotes (5)

[F1]Includes 837 shares of Common Stock received from Clarus Ventures III GP, L.P. in a pro rata distribution in-kind.
[F2]The transaction was executed in multiple trades in prices ranging from $35.78 to $35.86, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
[F3]The transaction was executed in multiple trades in prices ranging from $35.76 to $35.82, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
[F4]The Option vests with respect to 25% of the shares subject thereto on July 7, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
[F5]One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from April 10, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Documents

1 file

4
doc1.xmlPrimary
FORM 4

Issuer

Imago BioSciences, Inc.

CIK 0001623715

→

Entity typeother

Related Parties

filerCIK 0001861072

Filing Metadata

Form type: 4
Filed: Dec 18, 7:00 PM ET
Accepted: Dec 19, 4:11 PM ET
Size: 29.7 KB

View on SEC.gov